Business
Mainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe
Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in GermanyGANZIMMUN Diagnostics has an interdisciplinary team
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in GermanyGANZIMMUN Diagnostics has an interdisciplinary team of over 370 medical technical assistants, physicians, chemists, biologists, and nutritionists who process approximately 5,500 laboratory orders daily BERKELEY, Calif. and MAINZ, Germany, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with leading diagnostics laboratory GANZIMMUN Diagnostics AG (GD), one of Europe's leading laboratories for preventive and complementary medicine, for the commercialization in Germany of ColoAlert, Mainz’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer. Under the terms of the arrangement, Mainz will co-brand ColoAlert with GD, one of the largest stool analysis labs in Germany. GD will purchase Mainz’s customized polymerase chain reaction (PCR) assay kits to deliver its large network of physicians and their patients a comprehensive solution for advanced colorectal cancer prevention. These kits will be provided to GD on an on-demand basis and further expand coverage especially in Mainz, Wiesbaden and Frankfurt. “This is an important milestone for the company as we embark on executing a differentiated business model for ColoAlert from other at-home testing providers,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “As we launch ColoAlert across Europe, we are steadfast in executing our strategy to establish commercial partnerships with leading third-party laboratories to provide customers with the most efficient and reliable test results. I’m particularly pleased to have GANZIMMUN serve as one of our inaugural partners given its well-documented role serving as a premier laboratory.” GD has an interdisciplinary team of over 370 medical technical assistants, physicians, chemists, biologists, and nutritionists who process approximately 5,500 laboratory orders daily. The Company, which was founded in 1998, is based in Mainz, Rhineland-Palatinate, Germany and offers a state-of-the art facility with certified medical training available online and on-site. “On behalf of the entire GANZIMMUN team, I’m excited by the addition of ColoAle...